021-51111890
购物车（）
sales@molnova.cn
Belizatinib
CAS No. 1357920-84-3
Belizatinib ( TSR-011 | TSR011 )
产品货号. M11469 CAS No. 1357920-84-3
一种有效的双重 ALK 和 TrkA、TrkB 和 TrkC 抑制剂，对野生型重组 ALK 激酶活性具有高亲和力，IC50 为 0.7 nM。
纯度: >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| 规格 | 价格/人民币 | 库存 | 数量 |
| 2MG | ￥458 | 有现货 |
|
| 5MG | ￥787 | 有现货 |
|
| 10MG | ￥1264 | 有现货 |
|
| 25MG | ￥2474 | 有现货 |
|
| 50MG | ￥3469 | 有现货 |
|
| 100MG | ￥4473 | 有现货 |
|
| 500MG | ￥8883 | 有现货 |
|
| 1G | 获取报价 | 有现货 |
|
| 1 mL x 10 mM in DMSO | ￥945 | 有现货 |
|
生物学信息
-
产品名称Belizatinib
-
注意事项本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断
-
产品简述一种有效的双重 ALK 和 TrkA、TrkB 和 TrkC 抑制剂，对野生型重组 ALK 激酶活性具有高亲和力，IC50 为 0.7 nM。
-
产品描述A potent, dual ALK and TrkA, TrkB and TrkC inhibitor, exhibits high affinity for wild-type recombinant ALK kinase activity with IC50 of 0.7 nM; exerts sustained potent inhibition of ALK-dependent tumour growth in mouse models.Blood Cancer Phase 2 Clinical(In Vitro):TSR-011 has antitumour activity in the clinical trials.(In Vivo):TSR-011 exerts sustained potent inhibition of ALK-dependent tumour growth in mouse models.
-
体外实验TSR-011 has antitumour activity in the clinical trials.
-
体内实验TSR-011 exerts sustained potent inhibition of ALK-dependent tumour growth in mouse models.
-
同义词TSR-011 | TSR011
-
通路Tyrosine Kinase
-
靶点Trk Receptor
-
受体ALK
-
研究领域Cancer
-
适应症Blood cancer
化学信息
-
CAS Number1357920-84-3
-
分子量577.745
-
分子式C33H44FN5O3
-
纯度>98% (HPLC)
-
溶解度DMSO: ≥300 mg/mL （ < 1 mg/ml refers to the product slightly soluble or insoluble )
-
SMILESO=C(NC1=NC2=CC=C(CN3CCC(C(C)(O)C)CC3)C=C2N1[C@H]4CC[C@@H](C(NC(C)C)=O)CC4)C5=CC=C(F)C=C5
-
化学全称4-fluoro-N-(6-((4-(2-hydroxypropan-2-yl)piperidin-1-yl)methyl)-1-((1s,4s)-4-(isopropylcarbamoyl)cyclohexyl)-1H-benzo[d]imidazol-2-yl)benzamide
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1. Sullivan I, et al. Ther Adv Med Oncol. 2016 Jan;8(1):32-47.
2. Iams WT, et al. Cancer J. 2015 Sep-Oct;21(5):378-82.
3. Khotskaya YB, et al. Pharmacol Ther. 2017 May;173:58-66.
